ReEmerge Raises $37M for Cognitive Restoration Trial

The obligations attached to ReEmerge's $37M Series A begin where the announcement ends. The company has exited stealth with enough capital to move an investigational deep-brain-stimulation approach from a small academic feasibility result into a larger clinical program.

ReEmerge is developing Cognitive Network Restoration Therapy, or CNRT, for chronic cognitive impairment after traumatic brain injury. The central idea is unusually ambitious: stimulate underactive but still viable neural networks and test whether cognitive recovery can extend years after the injury, when rehabilitation has often shifted from restoration toward compensation.

The round was co-led by U.S. Venture Partners and Santé, with participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures. The proceeds are intended to support a new TBI study, continued technology development, expanded clinical and regulatory operations, and preparation of the platform for future indications.

What ReEmerge is building

ReEmerge describes CNRT as an investigational therapy that targets networks in the central thalamus, a brain hub involved in attention, arousal, and executive function. An implanted device delivers continuous low-voltage electrical pulses in an effort to drive circuits that remain structurally present but function below their earlier capacity after a brain injury.

That approach places the company inside neuromodulation, but its immediate claim is narrower than the category's commercial history. Deep brain stimulation is already used in other neurological settings, while ReEmerge's specific CNRT system for chronic TBI remains investigational and is not approved for commercial use in any geography. The company is attempting to establish a new therapeutic path, not repurpose an approved claim.

ReEmerge says its foundational intellectual property is exclusively licensed from Cornell University. The official company materials list Nicholas Schiff, MD; Jaimie Henderson, MD; Jonathan Baker, PhD; and Christopher Butson, PhD as scientific co-founders, linking work from Weill Cornell Medicine, Stanford University, and the University of Utah to the company's clinical program.

The evidence behind the new company

The research foundation includes a 2023 Phase 1 feasibility study published in Nature Medicine. Six people with chronic moderate-to-severe TBI, each 3 to 18 years after injury, underwent implantation. Five completed the study's outcome assessments, and their processing speed on Trail Making Test Part B improved by 15% to 52% from baseline, with an average improvement of 31.75%.

Those findings are meaningful because the participants were years into chronic recovery and all five completers exceeded the study's prespecified 10% improvement benchmark. They are also limited evidence. A five-person completed cohort can justify a larger study, but it cannot establish how consistently the therapy works, which patients benefit, how durable the effect is, or how the risk-benefit profile will look across a broader clinical population.

The distinction is central to the financing story. ReEmerge is not raising money around a finished treatment. It is financing the expensive translation from a promising signal into a reproducible clinical and regulatory record.

What the Series A will fund

The next step is ClinicalTrials.gov study NCT07730099, a prospective, single-arm, multicenter feasibility study sponsored by ReEmerge. The registry calls for up to 40 adults with chronic moderate-to-severe TBI at least 24 months after injury. It was listed as not yet recruiting when the record was last verified in July 2026, with an estimated February 2027 start and January 2029 completion.

The protocol is designed to evaluate safety and usability while exploring cognitive and functional outcomes. ReEmerge lists Lisa Fosdick, MS, the company's SVP of Clinical Affairs and Operations, as study director. CEO Todd Langevin leads an operating team that also includes Mike Labbe as SVP of R&D and Chris Pulling, MS, as VP of Analytics and Strategy.

For an implanted neuromodulation system, the operating burden reaches far beyond recruiting 40 people. Multicenter execution requires consistent imaging, surgical targeting, device management, outcome measurement, follow-up, data quality, and regulatory coordination. The company must carry the scientific specificity that produced the initial result into every site without assuming the result will reproduce itself.

Why chronic TBI is a difficult market to change

A BMJ Open analysis of Global Burden of Disease data estimated 27.16M new TBI cases worldwide in 2019. The number shows the scale of injury, but ReEmerge's initial market is more specific: adults with persistent cognitive impairment after moderate-to-severe TBI who are at least 2 years beyond the original event and meet a demanding study profile.

That focus creates both clinical importance and commercial complexity. The potential value is tied to attention, executive function, independence, work, and daily agency, outcomes that matter enormously to patients and families. The delivery model may still require specialized surgical centers, careful patient selection, long follow-up, reimbursement evidence, and coordination between neurosurgery, rehabilitation, neurology, and caregivers.

The investor group fits that kind of work. USVP invests across early-stage healthcare as well as technology, while Santé focuses on healthcare and medical innovation. The participating firms add more specialist capital, but the announcement does not disclose ownership, valuation, board changes, manufacturing partners, or commercial economics.

What operators should watch next

The first useful milestone is not a broad promise of restored cognition. It is the transition from a completed small study to an actively recruiting, consistently executed multicenter protocol. Study initiation, site selection, enrollment pace, safety reporting, and the definition of clinically meaningful outcomes will show whether ReEmerge can turn a scientific thesis into a durable development program.

The company also has to preserve the human meaning of its endpoint while meeting the discipline of regulated evidence. Faster performance on a cognitive test matters most when it connects to the choices a person can make, the work they can resume, and the independence they can regain. ReEmerge's Series A now finances the long route between those possibilities and evidence strong enough for clinicians, regulators, patients, and families to trust.